Patents Assigned to Boehringer Ingelheim International GmbH
  • Patent number: 11028169
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: June 8, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Haiguang Xiao, Danlin Yang
  • Publication number: 20210163449
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: December 8, 2020
    Publication date: June 3, 2021
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Publication number: 20210147393
    Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (1) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: January 27, 2021
    Publication date: May 20, 2021
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
  • Patent number: 11001570
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R5, X, Y and W have the meanings given in the claims and specification, their use as inhibitors of BCL6, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: May 11, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steffen Steurer, Georg Dahmann, Nina Kerres, Manfred Koegl
  • Patent number: 10973997
    Abstract: A nebulizer for nebulizing a liquid from a container is proposed. The nebulizer comprises a liquid pump for withdrawing the liquid in doses from the container and pressurizing the respective doses for nebulization. The nebulizer comprises in addition an air pump for temporarily pressurizing the liquid in the container to help withdrawing the liquid from a collapsible bag in the container.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: April 13, 2021
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Heinrich Kladders, Matthias Hausmann
  • Patent number: 10973827
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: April 13, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Friedl, Michael Braun, Kenji Egusa, Hikaru Fujita, Megumi Maruyama, Takaaki Nishioka
  • Publication number: 20210093807
    Abstract: A nebulizer for a fluid, includes a container containing the fluid; a housing part which can be detached from the nebulizer for replacing the container; an inner part; a retaining element connected with and not detachable from the inner part, where the housing part is releasable fixed to the inner part by the retaining element; a delivery mechanism for dispensing the fluid; a manually depressible actuator member, which is a separate part from the retaining element and acts on the retaining element, and wherein the actuator member is depressed to elastically deform or flex the retaining element to allow detachment of the housing part.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 1, 2021
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Jens Besseler, Frank Herrmann, Holger Holakovsky, Herbert Argauer, Josef Gatz, Andreas Gorshoefer
  • Patent number: 10953167
    Abstract: A system with a nebulizer as well as a container with a fluid and an indicator device for such a nebulizer are proposed. A check scheme is used for indicating the number of containers already used with the nebulizer or which still can be used with the nebulizer. The indicator device indicates the number of uses performed or still possible with the current container. The indicator device is adapted to let stepwise appear a color sequence and/or replacement symbol when approaching a predetermined number of uses with the container. Further, the indicator device can show markings in braille.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: March 23, 2021
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joachim Eicher, Andreas Fiol, Martin Meisenheimer
  • Patent number: 10954215
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: March 23, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Robert Owen Hughes, Xiang Li, Peter Allen Nemoto, Lana Louise Smith Keenan, Lifen Wu, Zhaoming Xiong
  • Patent number: 10947243
    Abstract: The invention relates to new substituted heteroaryls of formula 1 wherein A is selected from the group consisting of N and CH D is selected from the group consisting of CH, N, NH, S and O, E is selected from the group consisting of C and N, T is selected from the group consisting of C and N, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R1, M and R3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: March 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Georg Dahmann, Matthias Hoffmann, Jasna Klicic Badoux, David James Lamb, Clive McCarthy, Spencer Charles R. Napier, Karen Parrish, John Scott, Jennifer L. Swantek Fitzgerald, Edward Walker
  • Publication number: 20210070852
    Abstract: The present disclosure inter alia provides a liquid pharmaceutical formulation comprising a) 150 mg/ml of an anti-IL-23p19 antibody, wherein the antibody comprises a light chain amino acid sequence according to SEQ ID NO: 1 and a heavy chain amino acid sequence according to SEQ ID NO: 2; b) a polyol; and c) a surfactant. The disclosed high concentration formulations are advantageously storage stable and suitable for subcutaneous administration.
    Type: Application
    Filed: September 8, 2020
    Publication date: March 11, 2021
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Patrick Garidel, Torsten SCHULTZ-FADEMRECHT
  • Patent number: 10941137
    Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: March 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
  • Patent number: 10919898
    Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Steven Sand, Holger Rosenbrock, Riccardo Giovannini, Masashi Adachi, Bodo Betzemeier, Tobias Brodmann, Takayuki Kamata, Yohei Kawabata, Masanori Ito, Daniel Marckart, Manabu Nakatani, Ulrike Werthmann
  • Patent number: 10919859
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner, Stefan Peters
  • Patent number: 10918595
    Abstract: A process for the preparation of an oral disintegrating tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Manabu Nakatani, Yohei Kawabata, Takeshi Sawada, Hiroshi Takasaki
  • Patent number: 10919913
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Joachim Broeker, Annika Gille, Andreas Gollner, Manuel Henry, Nina Kerres, Harald Weinstabl
  • Patent number: 10913720
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: February 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner
  • Patent number: 10898661
    Abstract: A nebulizer as well as a container with a fluid for such a nebulizer are proposed. The container comprises a control device which indicates initially an unused state of the container before first use. An indicator device stops via a locking device further use of the container in a locked state when a predetermined number of uses has been reached or exceeded. After replacement of the container, the nebulizer can be reset and used again.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: January 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Andree Jung
  • Patent number: 10898487
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Kessler, Christiane Kofink, Matthew Russell Netherton, Juergen Ramharter, Tobias Wunberg
  • Patent number: D915584
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: April 6, 2021
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Arthur Eisenkrein, Oliver Koszel, Axel Roth